Background. Early identification of pathogens from blood cultures using matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry may optimize the choice of empirical antibiotic therapy in the setting of bloodstream infections. We aimed to assess the impact of this new technology on the use of antibiotic treatment in patients with gram-negative bacteremia.
sepsis [7, 8] . In the setting of bloodstream infections, MALDI-TOF applied to bacterial pellet obtained from positive blood culture is allowing a rapid identification of around 80% of pathogens. This identification is accurate in ≥99% of cases [4] [5] [6] . Identification of gram-negative pathogens has been shown to be very reliable, although the success rate is lower for gram-positive bacteria (mainly streptococci) and for encapsulated bacteria such as Klebsiella pneumoniae and Haemophilus influenzae [4] [5] [6] .
In clinical practice, the microbiology laboratory has an impact on the management of bloodstream infections at first by reporting the results of positive blood cultures. Munson et al demonstrated that the Gram stain result reported by telephone to the clinician had an even greater influence on the antibiotic regimen than antimicrobial susceptibility testing [9] . A same-day transmission of MALDI-TOF MS-based identification of the pathogen isolated from blood cultures would obviously represent another opportunity to increase the appropriateness of empirical antibiotic therapy. Although this strategy is theoretically promising, very few data are available analyzing the routine use of MALDI-TOF in this setting [10, 11] .
The aim of our study was thus to assess the impact of MALDI-TOF on the clinical management of gram-negative bacteremia. We prospectively performed MALDI-TOF MSbased bacterial identification on blood culture pellets immediately after Gram stain reporting [5] and assessed the impact of this procedure on antimicrobial treatment.
METHODS

Design and Case Definition
This prospective observational study was conducted between January and December 2010 in the University Hospital of Lausanne, an 850-bed primary and tertiary care hospital in Western Switzerland. Patients with a first episode of gramnegative bacteremia (including polymicrobial infections) for whom an infectious disease (ID) consultation was performed were included ( Figure 1 ). Data on successive antibiotic therapies were prospectively assessed by the clinical microbiologist when reporting the results to the clinicians using a standardized case report form (CRF). The sequence of antibiotic prescription was checked using the ID consultation report and a final CRF was filled in to include standardized clinical and epidemiological data. The impact of the Gram stain (first step) and the MALDI-TOF reporting (second step) on the antimicrobial management were assessed by 2 ID specialists (O. C. and G. G.) as described below. The primary outcomes were the respective and separate impacts of each step on the empirical antibiotic therapy. The design of this study was in accordance with the ethical standards of our local ethics committee.
Routine Procedures
Positive blood cultures were detected by the BACTEC 9240 automated blood culture system (Becton Dickinson, Sparks, MD). The microbiology laboratory ran daily from 8 AM to 5 PM. Gram stain was immediately performed on all positive blood cultures during this period and early the next morning when the blood cultures became positive overnight. Direct MALDI-TOF has been routinely performed in our center since September 2009 on all positive blood cultures immediately after the Gram staining. According to local procedure, pellets from positive blood cultures were prepared as described by Prod'hom et al [5] during the same day when bacterial growth was detected before 5 PM. Under these circumstances, Gram stain reporting was followed about 1 hour later by a second call to the clinician in charge of the patient in order to transmit the MALDI-TOF-based identification.
Mass spectra were acquired on a Microflex LT MALDI-TOF (Bruker Daltonics, Bremen, Germany). Spectral analysis and comparison with the database were performed using MALDI BioTyper 2.0 software. According to the criteria proposed by the manufacturer, an identification was considered reliable at the species level when the score value was x ≥ 2 and at the genus level when the score was 1.7 ≤ x < 2. Blood culture results were transmitted by clinical microbiologists directly to the clinicians and during a daily meeting to ID consultants. ID consultations were requested by clinicians in charge of the patients.
Hospital Setting
The incidence of gram-negative bacteria producing extended spectrum betalactamases (ESBL) was low according to the hospital microbiology database (<5% of all gram-negative bacilli). Similarly, community-associated ESBL-producing Escherichia coli remained rare in 2010 (3.4%, source: www. anresis.ch). Carbapenemase-producing organisms were not documented during the study period. As a consequence, third generation cephalosporins were the empirical first choice for non-AmpC-producing Enterobacteriaceae except in previously known ESBL carriers and in patients with severe sepsis or neutropenia, where broad spectrum antibiotic treatments were considered adequate. Fourth generation cephalosporins or carbapenems were chosen when AmpC-producing Enterobacteriaceae were detected. Our local antibiotic policy was summarized in local consensus guidelines developed by ID specialists and based on local epidemiology. These guidelines did not support the use of quinolones as empirical therapy.
Study Definitions
Polymicrobial bacteremia was defined as the isolation of >1 microorganism during the same bacteremic episode, except when the second microorganism was a coagulase-negative staphylococci (generally considered as a contaminant). A previous ESBL carriage was recorded according to the hospital infection control database. Immunosuppression included human immunodeficiency virus infection and specific medications ( prednisone equivalent ≥5 mg/d, cancer chemotherapy, tumor necrosis factor α inhibitors, and other immunosuppressive drugs). Penicillin allergy was included as stated in the medical record regardless of stage/gravity of the presumed reaction. A bacteremia was considered hospital-acquired if blood cultures were taken ≥48 hours after hospitalization. "Neutropenia" was defined as an absolute neutrophil cell count <0.5 × 10 9 neutrophils/L. "Severe sepsis" and "septic shock" were defined according to standard definitions [12] .
Streamlining was defined as the reduction of the antibiotic spectrum, either after Gram staining or after MALDI-TOF reporting, as for instance, the interruption of a specific anti-gram-positive coverage of vancomycin when only gramnegative pathogens were seen on the blood culture Gram stain. Similarly, "spectrum broadening" was defined after 1 of the 2 steps when the antibiotic coverage changed toward a broader spectrum. For instance, spectrum broadening occurred following MALDI-TOF reporting of Enterobacter cloacae, changing empirical therapy from ceftriaxone to cefepime. Gram stain could lead to the introduction of an empirical antibiotic therapy. MALDI-TOF reporting allowed the introduction of a focused empirical antibiotic therapy as, for instance, the introduction of an initial treatment with cefepime in case of the early detection of E. cloacae.
Statistics
Categorical variables were compared using the χ 2 or Fisher exact tests when appropriate; continuous variables were compared using the Mann-Whitney test. Analyses were conducted using the GraphPad Prism software, version 5.03 (GraphPad software, San Diego, CA).
RESULTS
General
There were 202 first episodes of gram-negative bacteremia leading to an ID consultation during the study period (Figure 1 ), among which 37 (18.3%) were polymicrobial and 120 (59.4%) were hospital-acquired. Main sources of infection were the digestive tract in 69 cases (34.2%), the urinary tract in 65 cases (32.2%), and intravascular catheters in 26 cases (12.9%) ( Table 1) . Among the 242 episodes of gram-negative bacteremia that were excluded as they did not lead to an ID consultation (Figure 1 and Supplementary Table) , 100 (41.3%) were diagnosed in the emergency department. Enterobacteriaceae were the more frequently identified clade, with 207 episodes (85.5% of all), among which were 146 cases of E. coli bacteremia. AmpC-producing bacteria were found in 23 cases (9.5% of all) and nonfermentative bacteria in 15 cases (6.2%).
Pathogens and Identification Scores (Table 2)
Among the 202 episodes of gram-negative bacteremia, 37 (18.3%) were polymicrobial and 165 (81.7%) were monomicrobial. Altogether, 143 of 165 episodes of monomicrobial bacteremia (86.7%) were correctly identified with a score ≥1.7. Among the 37 episodes of polymicrobial bacteremia, at least one pathogen could be reliably identified at the genus level in 28 cases (75.7%). Nevertheless, a correct identification at the genus level of all pathogens in a given polymicrobial blood culture was only possible in 11 of 37 cases (29.7%).
Among the 165 episodes of monomicrobial bacteremia, Enterobacteriaceae were documented in 120 cases (59.4%). MALDI-TOF identification performed on the blood culture pellet confirmed a high reliability for this bacterial family since 117 of all Enterobacteriaceae (97.5%) were correctly identified with a score ≥1.7. All 27 AmpC-producing Enterobacteriaceae species (13.4%) were correctly identified at the genus level.
Nonfermentative bacteria were documented in 25 of 202 cases, representing 12.4% of all cases. Pseudomonas spp. were identified in 9 of 22 cases (40.9%), whereas the other 3 nonfermentative bacteria were all correctly identified at species level.
Impact of Gram Stain and MALDI-TOF Reporting
The sequential impact of Gram stain and MALDI-TOF identification reporting on empirical antibiotic therapy are summarized in Figure 2 (Table 3) . MALDI-TOF identification had an impact on 16 of 27 episodes (59.3%) of monomicrobial bacteremia caused by AmpC-producing Enterobacteriaceae, whereas an impact was documented in only 39 of 93 cases (41.9%) of other Enterobacteriaceae. MALDI-TOF identification reporting had an impact in only 8 of 37 episodes (21.6%) of polymicrobial bacteremia, in only 6 of 25 episodes (24%) of monomicrobial bacteremia with nonfermentative bacteria and had no impact in the 4 previously known ESBL carriers. Impact of Gram stain reporting in cases of polymicrobial bacteremia (12 of 37 [32.4%]) was greater than that of MALDI-TOF MS.
Among the 131 cases where the MALDI-TOF did not lead to treatment modification, an impact would have been possible in 31 cases but no modification occurred. Factors associated with lack of modification of empirical antibiotic therapy are shown in Table 4 . Among these, intensive care unit (ICU) acquisition of bacteremia was associated with the absence of consideration of MALDI-TOF result, as were the male sex and younger age. Adaptation of antibiotic treatment was more likely for patients presenting with urosepsis (P = .06).
DISCUSSION
In this prospective, single-arm observational study including 202 episodes of gram-negative bloodstream infections, we observed that MALDI-TOF identification reporting had an impact on antibiotic therapy in 35.1% of bacteremia, whereas Gram stain had an impact in 20.8% of cases. In addition, we confirmed the excellent reliability of MALDI-TOF for bacterial identification on blood culture pellets outside of validation studies, [4] [5] [6] in the real-life setting of routine microbiology practice. As previously reported, the reliability of this new technology was especially high for Enterobacteriaceae [4] [5] [6] . A maximal impact was observed when AmpC-producing Enterobacteriaceae were documented, given their particular pattern of antibiotic resistance. As already published, [4, 13] we documented a lower reliability of MALDI-TOF in cases of polymicrobial bacteremia, a situation where the Gram stain result is more informative. Thus, this justifies always performing direct Gram staining examination of any positive blood cultures even in the MALDI-TOF era.
Reducing the time to result in clinical microbiology has been achieved using various approaches and aims (1) to impact on the clinical outcome of patients, (2) to optimize the use of antibiotics, and (3) to reduce costs [14] [15] [16] [17] . Gram stain reporting is part of routine management of bloodstream infections, as it has been shown to have the greatest impact on antimicrobial empirical therapy [9] . Improvement in Gram stain turnaround time has even been associated with a decrease in patient mortality [18] . Indeed, as early appropriate antibiotic therapy has been shown to reduce the mortality of bloodstream infections [19] , there is an obvious need for techniques that could increase initial antibiotic appropriateness. Although there have been numerous publications in the recent years on the additional value of bacterial identification with MALDI-TOF in blood cultures [4-6, 13, 20] , there are few data on the clinical impact of this new strategy to justify its implementation in routine practice. Vlek et al compared 2 sequential periods in a prospective study: one standard period during which only Gram staining and results of susceptibility testing could influence the antibiotic therapy, and one intervention period in which MALDI-TOF was added to study its possible impact on empirical treatment. Among 253 episodes of bacteremia, 89 led to MALDI-TOF identification with an early correct identification in 56.2% of episodes. The application of MALDI-TOF increased the proportion of appropriate treatments within 24 hours of blood culture positivity by 11.3% [10] . Hodiamont et al recently presented unpublished data showing that the addition of MALDI-TOF identification to Gram stain reporting led to an early adaptation of antibiotic therapy in up to 29% of 73 cases of bloodstream infection [11] . Both studies came from the Netherlands, where the incidence of antimicrobial resistance remains low. Our data from a country with low but increasing ESBL prevalence are in line with these 2 studies. Our study has limitations. Its single arm, observational design precluded us from evaluating the impact of MALDI-TOF on the clinical outcome of patients as, in our hospital, MALDI-TOF has been included in the routine management of blood cultures since we initially validated this approach [5] . We included only those cases managed with the help of an ID consultation, as these were clinically the most relevant and as the resulting report allowed us to obtain precise information regarding the sequence of antibiotic therapy. The overrepresentation of non-AmpC-producing Enterobacteriaceae (mostly E. coli) in the 242 cases that were excluded and the predominance of ambulatory cases in that group suggest that, among these 242 cases, there were more common infections such as urosepsis, for which the impact of MALDI-TOF identification might be less important and might be managed without the need of an ID consultation. However, this study design corresponds to the routine clinical management of gram-negative bacteremia in our hospital and probably in many others. In this sense, we think that our results are useful to estimate the true benefits of this new technology in a real-life setting. Our study was conducted in a low-prevalence area for ESBL and for multiresistant gram-negative bacteria, which could possibly lead to an overestimation of the impact of MALDI-TOF MS. Finally, prescription of an empirical antibiotic therapy is a complex decision involving epidemiological considerations, severity of disease and experience or education of the clinician in charge, as suggested by the determinants of the effective impact of MALDI-TOF MS. The impact of MALDI-TOF may thus vary according to the epidemiological setting, the site where bacteremia was managed ( particularly ICU) or the presumed site of infection. Indeed, clinicians might feel more comfortable with the early identification of bacteria using an unfamiliar technology if the urinary tract was the suspected source of bacteremia, as uropathogens might be more predictable than pathogens from a suspected catheter infection. Further studies including educational approaches might help to target these hypotheses.
The main strength of our study is that we document the clinical application of MALDI-TOF performed directly on blood culture pellets, as well as its successful implementation in routine clinical microbiology. Indeed, we observed that this new technology had an impact in more than one-third of all episodes of gram-negative bacteremia. Although these findings should be confirmed by larger, randomized studies including clinical outcomes, our data suggest that rapid MALDI-TOF MS-based identification of bacteria grown from blood cultures could become a second critical step in the management of patients with positive blood cultures besides Gram stain reporting.
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